WVEWave Life Sciences Ltd

The consensus price target hints at a 294.7% upside potential for Wave Life Sciences (WVE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter...

Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C., May 19, 2026 The...

The Cambridge-based biotech said its drug WVE-006 produced promising effects in patients with the most severe form of alpha-1 antitrypsin deficiency.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Equities research analysts at HC Wainwright upped their Q2 2026 earnings estimates for WAVE Life Sciences in a report issued on Wednesday, April 29th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.3...

Pictet Asset Management Holding SA boosted its holdings in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 5,024.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 805...

Wall Street Zen raised shares of WAVE Life Sciences from a "strong sell" rating to a "hold" rating in a research report on Saturday...